-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Jj2qIFvHcQ0geBrOvenWcNT8j9lX26kyKtTc7xuDlw+pZ+xkFIst7fx6B7V1TkXr mdrGo46OahZ3NwFQCH36CQ== 0001209191-07-006905.txt : 20070201 0001209191-07-006905.hdr.sgml : 20070201 20070201192223 ACCESSION NUMBER: 0001209191-07-006905 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070126 FILED AS OF DATE: 20070201 DATE AS OF CHANGE: 20070201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Solexa, Inc. CENTRAL INDEX KEY: 0000913275 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 943161073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 25861 INDUSTRIAL BLVD CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 MAIL ADDRESS: STREET 1: 25861 INDUSTRIAL BLVD CITY: HAYWARD STATE: CA ZIP: 94545 FORMER COMPANY: FORMER CONFORMED NAME: LYNX THERAPEUTICS INC DATE OF NAME CHANGE: 19931008 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Omead Ostadan CENTRAL INDEX KEY: 0001368212 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-22570 FILM NUMBER: 07573305 BUSINESS ADDRESS: BUSINESS PHONE: 510-670-9300 MAIL ADDRESS: STREET 1: SOLEXA, INC. STREET 2: 25861 INDUSTRIAL BLVD. CITY: HAYWARD STATE: CA ZIP: 94545 4/A 1 bsf26824_bsf15oo.xml MAIN DOCUMENT DESCRIPTION X0202 4/A 2007-01-26 2007-01-30 1 0000913275 Solexa, Inc. SLXA 0001368212 Omead Ostadan C/O SOLEXA, INC. 25861 INDUSTRIAL BLVD. HAYWARD CA 94545 0 1 0 0 VP Marketing Stock Option (Right to Buy) 6.11 2007-01-26 4 D 0 35000 0.00 D 2015-06-03 Common Stock 35000 0 D Stock Option (Right to Buy) 8.60 2007-01-26 4 D 0 75000 0.00 D 2016-02-02 Common Stock 75000 0 D This option, which provided for vesting of 25% on the one year anniversary of May 31, 2006 and monthly thereafter over 36 months, was assumed by Illumina, Inc. in connection with the merger with Solexa, Inc. and replaced with an option to purchase 12,040 shares at an exercise price of $17.76 per share. This option, which provided for vesting monthly and ratably over the 48 month period beginning on February 2, 2006 was assumed by Illumina, Inc. in connection with the merger with Solexa, Inc. and replaced with an option to purchase 25,800 shares at an exercise price of $25.00 per share. /s/ Omead Ostadan, by Kathy San Roman, attorney-in-fact 2007-02-01 -----END PRIVACY-ENHANCED MESSAGE-----